Clinical Trial Update: Allo HSCT for High Risk Hemoglobinopathies [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating allogeneic hematopoietic stem cell transplantation for high-risk hemoglobinopathies, including sickle cell disease; cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Graft Failure, Sickle Cell Disease | Phase 2 | Status: RECRUITING